Ikarian Capital’s Silence Therapeutics SLN Stock Holding History

Ikarian Capital’s Portfolio SLN Stock Details SLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.83M	Sell	830,784 -35,000	-4%	-$246K	0.2%	90
2026 Q1	$1.73M	Hold	865,784	–	–	0.14%	104
2025 Q4	$1.73M	Sell	865,784 -35,000	-4%	-$224K	0.14%	107
2025 Q3	$1.31M	Buy	900,784 +27,216	+3%	+$151K	0.13%	114
2025 Q2	$1.4M	Buy	+873,568	New	+$3.75M	0.27%	74
2024 Q4	–	Sell	-587,343	Closed	-$3.37M	–	201
2024 Q3	$3.37M	Buy	587,343 +80,678	+16%	+$1.5M	0.47%	59
2024 Q2	$3.29M	Buy	+506,665	New	+$10.8M	0.57%	40

Other funds holding SLN

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Ikarian Capital's SLN Position: Q2 2026 in Review

Ikarian Capital reduced its Silence Therapeutics (SLN) stake by 4% in Q2 2026, selling an estimated $246K and leaving 830,784 shares worth $1.83M. The position accounts for 0.2% of the portfolio, ranked #90.

Ikarian Capital first reported a position in SLN in Q2 2024 and has held it in 7 quarters since. The position peaked at $3.37M in Q3 2024. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

Ikarian Capital held 830,784 shares of Silence Therapeutics worth $1.83M as of Q2 2026.
Ikarian Capital sold 35,000 Silence Therapeutics shares in Q2 2026, an estimated $246K.
Silence Therapeutics made up 0.2% of Ikarian Capital's portfolio in Q2 2026, its #90 holding.
Ikarian Capital first reported a position in Silence Therapeutics in Q2 2024 and has held it in 7 quarters since.
Ikarian Capital's Silence Therapeutics position peaked at $3.37M in Q3 2024.
72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.